Skip to main content
Top
Published in: Journal of Gastroenterology 1/2005

01-01-2005 | Case report

A case of leptomeningeal carcinomatosis from esophageal basaloid carcinoma diagnosed by quantitative reverse transcription-polymerase chain reaction for carcinoembryonic antigen

Authors: Hiroshi Okumura, Shoji Natsugoe, Naoya Yokomakura, Yuko Mataki, Yusei Haraguchi, Hironori Sakita, Yukio Mihara, Masataka Matsumoto, Shin-Ichi Imamura, Jun-Ichi Kuratsu, Sumiya Ishigami, Sonshin Takao, Takashi Aikou

Published in: Journal of Gastroenterology | Issue 1/2005

Login to get access
Metadata
Title
A case of leptomeningeal carcinomatosis from esophageal basaloid carcinoma diagnosed by quantitative reverse transcription-polymerase chain reaction for carcinoembryonic antigen
Authors
Hiroshi Okumura
Shoji Natsugoe
Naoya Yokomakura
Yuko Mataki
Yusei Haraguchi
Hironori Sakita
Yukio Mihara
Masataka Matsumoto
Shin-Ichi Imamura
Jun-Ichi Kuratsu
Sumiya Ishigami
Sonshin Takao
Takashi Aikou
Publication date
01-01-2005
Publisher
Springer-Verlag
Published in
Journal of Gastroenterology / Issue 1/2005
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-004-1498-3

Other articles of this Issue 1/2005

Journal of Gastroenterology 1/2005 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine